US 9,956,196 B2 · Use of monosaccharide-like glycylated sugar alcohol compositions for designing and developing anti-diabetic drugs

Abstract

This invention is related to a novel sugar-like chemical composition and its use for diabetes therapy. Particularly, the present invention teaches the use of monosaccharide-like glycylated sugar alcohol compounds to block or reduce sugar absorption in diabetes patients, so as to prevent the risk of hyperglycemia symptoms. Glycylation of sugar alcohols is a totally novel reaction that has never been reported before. Therefore, the novelty of the present invention is that for the first time glycylated sugar alcohols not only was found but also was found to be useful for treating Diabetes mellitus. In addition, the present invention teaches a method for producing these glycylated sugar alcohols. In sum, the present invention includes not only a kind of novel sugar-like chemical compositions and its use for treating diabetes but also a state-of-the-art protocol and methodology for producing such a novel composition via glycylation of sugars and sugar alcohols.

Claims12

Dependent claims

A composition of a drug ingredient for treating hyperglycemia and obesity of diabetes mellitus, comprising:

monoglycylglycerol (monoglycylglycerin;
MGG), wherein the monoglycylglycerol (monoglycylglycerin;
MGG) is formulated as an oral administration form, and the monoglycylglycerol (monoglycylglycerin;
MGG) is orally applied at a dosage at least 1 milligram (≥1 mg) but no more than 2.5% ( 1/40) of the body weight of a subject suffering from diabetes mellitus,
wherein the monoglycylglycerol (monoglycylglycerin;
MGG) has a chemical formula of NH2CH2CO(HCHO)3H.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application

14/585,978Filed 30 Dec 2014 · continuation in part

Priority

26 Jan 2014

Published

US 2015/0209377 A130 Jul 2015

Granted

1 May 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 31/221
Of acyclic acids, e.g. pravastatin: with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/08
Medicinal preparations characterised by special physical form: solutions
A61K 31/7012
Carbohydrates; Sugars; Derivatives thereof: compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to…

Family

Application61/931,650Us provisional application · filed 26 Jan 2014

Application14/457,829Parent of this continuation-in-part · filed 12 Aug 2014

Application62/050,107Us provisional application · filed 13 Sep 2014

Application62/054,981Us provisional application · filed 25 Sep 2014

US 2015/0209377 A1Pre-grant publication · published 30 Jul 2015

US 9,387,251 B2Parent of this continuation-in-part

US 2014/0350085 A1Published application

US 9,956,196 B2This patent

From the US filing history. Foreign family members aren’t listed.

Use of monosaccharide-like glycylated sugar alcohol compositions for designing and developing anti-diabetic drugs

Life of this patent

Use of monosaccharide-like glycylated sugar alcohol compositions for designing and developing anti-diabetic drugs

Life of this patent

Abstract

Claims12